Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (673)	6/20/1998 8:17:00 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 1686

Biogen did say they are well prepared to protect their CD40L position, but the phrasing was really mine. It encapsulates Jim Tobin's sentiments, but he is too professional to put it exactly that way. He did say that Biogen is pursuing an unusual tactic (for Biogen) in that they are running trials for many indications simultaneously for 5C8 and expect to leave Idec slim pickings at any rate. Another interesting note: Jim Tobin said that 4 of the 18 protein-based products on the market with annual revenues of over $100MM were developed by Biogen.